A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Phase 2 Active not recruiting 3 enrolled M.D. Anderson Cancer Center Amgen · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a single arm open-label phase 2 trial to study the safety and efficacy of SC Blinatumomab in combination with low-intensity chemotherapy for older or unfit patients with B-ALL.

Timeline

Start: 2026-01-30
Primary completion: 2031-09-30
Completion: 2033-09-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Blinatumomab	Monoclonal antibody	—	Subcutaneous
Background	Cytarabine	Small molecule	—	Intravenous
Background	MTX	Unknown	—	Intravenous

A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

Summary

Timeline

Drugs

Indications